Sarah Diepstraten

Sarah Diepstraten

Senior Research Officer, Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute
Sarah Diepstraten completed her PhD at La Trobe University in molecular genetics and developmental biology. She is now a post-doctoral scientist at the Walter and Eliza Hall Institute. Her research focuses on understanding how blood cancers become resistant to therapy and how this can be overcome. She develops genetic engineering approaches (CRISPR) to find genes involved in drug resistance. She has also taught in undergraduate science courses at La Trobe University and Melbourne University, and is passionate about science education.

More from this expert

The anti-cancer drug abemaciclib (also known as Vernezio) has this month been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer.

Clinical Articles iconClinical Articles

Upcoming Healthed Webcast

Premature Ovarian Insufficiency – The New Guidelines

Tuesday 3rd March, 7pm - 9pm AEDT

Speaker

Prof Rodney Baber AM

Obstetrician and Gynaecologist; Clinical Professor, Uni of Sydney

Join Prof Rodney Baber AM for this presentation where he will discuss the new guidelines related to POI and the most relevant recommendations for GPs.